MX2023000447A - Antagonista de receptor de tromboxano formulaciones. - Google Patents
Antagonista de receptor de tromboxano formulaciones.Info
- Publication number
- MX2023000447A MX2023000447A MX2023000447A MX2023000447A MX2023000447A MX 2023000447 A MX2023000447 A MX 2023000447A MX 2023000447 A MX2023000447 A MX 2023000447A MX 2023000447 A MX2023000447 A MX 2023000447A MX 2023000447 A MX2023000447 A MX 2023000447A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- thromboxane
- receptor antagonist
- thromboxane receptor
- formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940122202 Thromboxane receptor antagonist Drugs 0.000 title 1
- 239000002396 thromboxane receptor blocking agent Substances 0.000 title 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 abstract 3
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 102000003938 Thromboxane Receptors Human genes 0.000 abstract 1
- 108090000300 Thromboxane Receptors Proteins 0.000 abstract 1
- GHDLZGOOOLEJKI-UHFFFAOYSA-N benzenesulfonylurea Chemical compound NC(=O)NS(=O)(=O)C1=CC=CC=C1 GHDLZGOOOLEJKI-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229940127293 prostanoid Drugs 0.000 abstract 1
- 150000003814 prostanoids Chemical class 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona formulaciones que mejora biodisponibilidad de antagonistas de receptor de tromboxano que les permite unirse a los receptores de tromboxano A2 en sujetos que sufren de indicaciones de enfermedad en las cuales el prostanoide tromboxano A2, y ligandos incidentales de receptor de tromboxano A2, se implican; las formulaciones comprenden una dispersión sólida que comprende una bencenosulfonilurea y un polímero que son adecuados para administración a través de vías de suministro orales u otras.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063048856P | 2020-07-07 | 2020-07-07 | |
| PCT/EP2021/068672 WO2022008515A1 (en) | 2020-07-07 | 2021-07-06 | Thromboxane receptor antagonist formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000447A true MX2023000447A (es) | 2023-04-20 |
Family
ID=77155731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000447A MX2023000447A (es) | 2020-07-07 | 2021-07-06 | Antagonista de receptor de tromboxano formulaciones. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230301946A1 (es) |
| EP (1) | EP4178547A1 (es) |
| JP (1) | JP2023533029A (es) |
| KR (1) | KR20230035601A (es) |
| CN (1) | CN116234539A (es) |
| AU (1) | AU2021304808A1 (es) |
| BR (1) | BR112023000168A2 (es) |
| CA (1) | CA3188796A1 (es) |
| MX (1) | MX2023000447A (es) |
| WO (1) | WO2022008515A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| AU7292398A (en) | 1997-05-15 | 1998-12-08 | Eli Lilly And Company | Antithrombotic compound |
| US7202247B2 (en) | 2001-12-19 | 2007-04-10 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
| US20050008704A1 (en) * | 2003-07-11 | 2005-01-13 | Ray Anup Kumar | Pharmaceutical composition for solubility enhancement of hydrophobic drugs |
| KR20050045630A (ko) * | 2003-11-12 | 2005-05-17 | 동아제약주식회사 | 미립자화 된 글리메피리드, 미립자화 방법 및 그를함유하는 제제 |
| KR102095698B1 (ko) * | 2010-10-29 | 2020-04-01 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
| WO2013156861A2 (en) * | 2012-04-17 | 2013-10-24 | University College Dublin, National University Of Ireland, Dublin | Methods and compounds for treating proliferative disorders and viral infections |
| WO2013156871A2 (en) * | 2012-04-17 | 2013-10-24 | University College Dublin, National University Of Ireland, Dublin | Thromboxane receptor antagonists |
| CN105208668B (zh) | 2014-06-06 | 2019-06-18 | 上海诺基亚贝尔股份有限公司 | 一种载波侦听方法 |
| ES2858551T3 (es) * | 2015-06-16 | 2021-09-30 | Atxa Therapeutics Ltd | Antagonistas del receptor de tromboxano |
-
2021
- 2021-07-06 WO PCT/EP2021/068672 patent/WO2022008515A1/en active Application Filing
- 2021-07-06 KR KR1020237003944A patent/KR20230035601A/ko unknown
- 2021-07-06 EP EP21748790.9A patent/EP4178547A1/en active Pending
- 2021-07-06 CA CA3188796A patent/CA3188796A1/en active Pending
- 2021-07-06 JP JP2023501078A patent/JP2023533029A/ja active Pending
- 2021-07-06 BR BR112023000168A patent/BR112023000168A2/pt unknown
- 2021-07-06 CN CN202180051894.5A patent/CN116234539A/zh active Pending
- 2021-07-06 AU AU2021304808A patent/AU2021304808A1/en active Pending
- 2021-07-06 US US18/014,438 patent/US20230301946A1/en active Pending
- 2021-07-06 MX MX2023000447A patent/MX2023000447A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023000168A2 (pt) | 2023-01-31 |
| CA3188796A1 (en) | 2022-01-13 |
| JP2023533029A (ja) | 2023-08-01 |
| WO2022008515A1 (en) | 2022-01-13 |
| EP4178547A1 (en) | 2023-05-17 |
| CN116234539A (zh) | 2023-06-06 |
| AU2021304808A1 (en) | 2023-02-09 |
| KR20230035601A (ko) | 2023-03-14 |
| US20230301946A1 (en) | 2023-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Menezes et al. | The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo | |
| FI3618842T3 (fi) | Soluterapian ja immunomodulatorisen yhdisteen yhdistelmä | |
| Carter et al. | Maraviroc | |
| DK1149078T3 (da) | Selektive 5-HT6-receptorligander | |
| EA201101009A1 (ru) | АНТАГОНИСТЫ C5aR | |
| DK0760811T3 (da) | Imidazolderivater som histaminreceptor H3-modulatorer | |
| MA38147B1 (fr) | Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique | |
| ATE298343T1 (de) | Ligande für metabotropische glutamat-rezeptoren | |
| NO20062088L (no) | Farmasoytisk preparat som omfatter en selektiv I1-imidazolinreseptoragonist og en angiotensin II-reseptorblokker | |
| MA34296B1 (fr) | Composition retard injectable antipsychotique | |
| Kaye et al. | Novel pharmacological nonopioid therapies in chronic pain | |
| DE60039921D1 (de) | Hochaffine kleinmolekülige c5a-rezeptor-modulatoren | |
| RU2017106172A (ru) | Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn) | |
| MA31941B1 (fr) | Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine | |
| HK1105197A1 (en) | Pyrimido-benzimidazole derivatives and the use thereof in the form of agonists or antagonists of melanocortin receptors | |
| PH12014502331A1 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
| MA55821B1 (fr) | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression | |
| PE20121131A1 (es) | Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina | |
| MX2023000447A (es) | Antagonista de receptor de tromboxano formulaciones. | |
| SE9702651D0 (sv) | Novel compounds | |
| Oparil et al. | Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension | |
| MX2022016445A (es) | Antagonistas del receptor de glucocorticoides de indazol cuaternario. | |
| ATE509632T1 (de) | Behandlung von entzündlicher darmerkrankung | |
| EA201892583A1 (ru) | Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора | |
| TR200301553A1 (tr) | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar |